Frampton, James E.
Silberstein, Stephen
Article History
First Online: 12 March 2018
Change Date: 20 April 2018
Change Type: Correction
Change Details: The article OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine, written by James E. Frampton and Stephen Silberstein, was originally published Online First without open access. After publication in volume 78, issue 5, pages 589–600 [funder] requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by [funder]. Further details may be found at [MedEngine webpage link].
Compliance with Ethical Standards
:
: The preparation of this review was not supported by any external funding.
: James Frampton is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.As a consultant and/or advisory panel member, Stephen Silberstein receives, or has received, honoraria from: Alder Biopharmaceuticals; Allergan, Inc.; Amgen; Avanir Pharmaceuticals, Inc.; Curelator, Inc.; Depomed; Dr. Reddy’s Laboratories; eNeura Inc.; electroCore Medical, LLC; INSYS Therapeutics; Labrys Biologics; Lilly USA, LLC; Medscape, LLC; Medtronic, Inc.; Neuralieve; NINDS; Pfizer, Inc.; Supernus Pharmaceuticals, Inc.; Teva Pharmaceuticals; Theranica; and Trigemina, Inc.Additional information about this Adis Drug Review can be found at ExternalRef removed.